KEI statement on GSK’s announcement of policies to expand access to patented medicines
GSK has made a major announcement of new policies to expand access to its patented medicines. A copy of the press statement is here. Continue Reading
Xtandi March-in Request, links to news stories, blogs
Sanofi $9.3 Billion Medivation Bid 28 April 2016. Ben Hirschler and Leigh Thomas. Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation. Reuters. 28 April 2016. Helen Thomas. Sanofi / Medivation: Deal-Making Déjà Vu Comes With Added Competition. WSJ.… Continue Reading
Bicameral letter from 6 Senators and 6 members of the House to NIH
On March 28, 2016, six Senators and six members of the House of Representatives sent a letter to HHS Secretary Burwell and Director Collins at NIH, calling for an “open and transparent public hearing” to discuss the issues presented in… Continue Reading
The WSJ on Doha Declaration on TRIPS and Public Health, in 2001
This was the Wall Street Journal’s take on the Doha Declaration on TRIPS and Public Health, two days after the agreement was reached:
11 Groups Urge NIH to Lower Price of Xtandi, NIH/Army-Funded Prostate Cancer Drug With $129k/Year Price Tag
CONTACT:
Zack Struver
zack.struver@keionline.org
+1 (914) 582-1428
FOR RELEASE: MARCH 21, 2016
Non-Profit Groups Urge Obama Administration, NIH to Lower Price of Government-Funded, $129,000 Per Year Prostate Cancer Drug
The groups asked the National Institutes of Health to “take this opportunity to act” to lower the price of the prostate cancer drug Xtandi and show leadership on deterring discriminatory pricing practices.
TDR releases report on a Health Product Research & Development Fund: A Proposal for Financing and Operation
On 17 March 2016, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) released a 76-page report entitled, Health Product Research & Development Fund: A Proposal for Financing and Operation.
Update on our work on US government owned patents
I have provided an update on our work on US government owned patents here:
Briefing on Beijing Treaty on Audiovisual Performers
On Monday, March 7, 2016, from 1:45 P.M. to 2:45 P.M., the US Patent and Trademark Office (USPTO) met with invited stakeholders in a briefing at the White House on the Beijing Treaty on Audiovisual Performances and the implementation package that was sent to Congress on February 29, 2016. The package was submitted for review to the Senate Foreign Relations and Judiciary Committees.
2016: KEI/MSF comments to NIH on licensing of patents on Attenuated Respiratory Syncytial Virus (RSV) Vaccines
Other KEI comments on NIH licenses can be found here: /nih-licenses
Congressman Doggett Voices Support for KEI/UACT Petition to NIH on Xtandi
On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.